Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Estimates By $0.20 EPS

Lyell Immunopharma (NASDAQ:LYEL) announced its quarterly earnings data on Wednesday. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.20, Zacks reports. Lyell Immunopharma had a negative return on equity of 101.30% and a negative net margin of 1,701,066.75%. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL traded down $0.14 during trading on Friday, hitting $14.86. 250,691 shares of the company traded hands, compared to its average volume of 140,482. The business’s fifty day moving average is $10.85 and its 200 day moving average is $16.69. Lyell Immunopharma has a fifty-two week low of $7.20 and a fifty-two week high of $45.00. The firm has a market capitalization of $364.13 million, a price-to-earnings ratio of -1.18 and a beta of -0.04.

Wall Street Analyst Weigh In

Several research firms recently commented on LYEL. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, October 25th. Stifel Nicolaus started coverage on Lyell Immunopharma in a research note on Thursday, August 6th. They issued a “buy” rating and a $36.00 price target on the stock. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.86.

Lyell Immunopharma News Summary

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Promising ronde-cel results: Updated results showed high response rates in patients with large B-cell lymphoma: 91% overall and 77% complete responses in a 44-patient group, with similarly strong results in a second-line cohort. No severe cytokine release syndrome was reported in either group. The data may support ronde-cel’s development and planned regulatory path. Ronde-cel clinical data
• Positive Sentiment: $80 million financing and major-shareholder buying: Lyell plans to raise about $80 million to advance ronde-cel toward a biologics license application. ARCH-affiliated entities disclosed a purchase of 2.32 million shares for about $25 million at $10.77 per share, increasing the reported position by 162.72%. This may signal investor confidence, though the purchase reports appear to describe the same transaction. Financing announcement SEC transaction filing
• Positive Sentiment: Buy rating and earnings beat: Needham reiterated a “Buy” rating. Lyell’s quarterly loss of $1.86 per share was narrower than the $2.06 consensus estimate. Needham rating Quarterly results
• Negative Sentiment: Dilution and ongoing cash burn: The private placement entails issuing additional shares, diluting current holders. Lyell reported no quarterly revenue and remains loss-making, leaving its prospects dependent on clinical and regulatory progress.

Insider Transactions at Lyell Immunopharma

In other news, major shareholder Arch Venture Partners Ix, Llc bought 2,321,262 shares of Lyell Immunopharma stock in a transaction dated Wednesday, November 4th. The stock was bought at an average cost of $10.77 per share, for a total transaction of $24,999,991.74. Following the purchase, the insider directly owned 3,747,790 shares in the company, valued at approximately $40,363,698.30. This represents a 162.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Venture Fund Xiii L.P. Arch bought 2,321,262 shares of Lyell Immunopharma stock in a transaction dated Wednesday, November 4th. The stock was purchased at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the completion of the purchase, the insider owned 3,747,790 shares in the company, valued at $40,363,698.30. This trade represents a 162.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 1,763 shares of company stock worth $22,052 in the last three months. Insiders own 6.20% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.